This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.


EXPLORE ELIQUIS®

NVAF

Explore ELIQUIS for stroke
prevention in non-valvular
atrial fibrillation with one or
more risk factors for stroke

DVT / PE

Explore ELIQUIS in deep
vein thrombosis / pulmonary
embolism

PRESCRIBING ELIQUIS

ADDITIONAL SUPPORT

Patient
Materials

Medical
Education

FOOTNOTES

DVT = Deep Vein Thrombosis
  MHRA = Medicines and Healthcare products Regulatory Agency
  NVAF = Non-Valvular Atrial Fibrillation
PE = Pulmonary Embolism